Wolkersdörfer G W, Morris J C, Ehninger G, Ramsey W J
Medical Department I, Faculty of Medicine, Technical University of Dresden, 01307 Dresden, Germany.
J Gene Med. 2004 Jun;6(6):652-62. doi: 10.1002/jgm.551.
Despite attempts to develop efficient viral-based gene transfer therapies for the treatment of malignant tumors, only limited progress has been made to improve the efficacy of this approach. As an alternative, the use of replicating oncolytic adenoviruses with and without the expression of therapeutic transgenes is an area of active investigation.
We used a human melanoma xenograft tumor nude mouse model to test the efficacy of a bivalent vector approach consisting of two trans-complementing replication-incompetent adenoviral vectors that resulted in tumor-restricted oncolysis. We combined an E1-deleted non-replicating adenoviral vector expressing the herpes simplex virus thymidine kinase gene (AV.C2.TK) and Ad5.dl1014, an E4-deleted/E4orf4-only expressing adenovirus, to allow full replication competence when tumor cells were co-infected with both vectors.
A375 tumors showed apoptosis at the ultrastructural level after transduction with the trans-complementing vector system that was not seen with injection of either vector alone. Apoptotic DNA fragments could be co-localized to sites of infection with the adenoviral vectors. A significant survival benefit was achieved for the trans-complementing vector treated animals compared to animals treated with either vector alone. Interestingly, the administration of GCV did not further increase animal survival over treatment with the trans-complementing system of viruses alone, and long-term survival was only seen in the trans-complementing vector treatment group. Intraperitoneal administration of a pseudo-wild-type vector Ad.dl327 resulted in significant hepatotoxicity, while intraperitoneal administration of the trans-complementing vectors resulted in only mild liver abnormalities.
The trans-complementing vector approach using a combination of E1- and E4-deleted adenoviral vectors showed similar antitumor efficacy as reported for monovalent replicating vector systems, but may offer additional safety by reducing the risk of dissemination of the replication-competent vectors by requiring the presence of both vectors in a cell to achieve replication competence.
尽管人们试图开发高效的基于病毒的基因转移疗法来治疗恶性肿瘤,但在提高这种方法的疗效方面仅取得了有限的进展。作为一种替代方法,使用携带或不携带治疗性转基因表达的复制型溶瘤腺病毒是一个活跃的研究领域。
我们使用人黑色素瘤异种移植瘤裸鼠模型来测试一种二价载体方法的疗效,该方法由两种反式互补的无复制能力腺病毒载体组成,可导致肿瘤特异性溶瘤。我们将表达单纯疱疹病毒胸苷激酶基因的E1缺失的非复制性腺病毒载体(AV.C2.TK)和Ad5.dl1014(一种E4缺失/仅表达E4orf4的腺病毒)相结合,当肿瘤细胞同时被这两种载体感染时可实现完全复制能力。
用反式互补载体系统转导后,A375肿瘤在超微结构水平上显示出凋亡,而单独注射任何一种载体时均未观察到这种情况。凋亡DNA片段可与腺病毒载体的感染部位共定位。与单独用任何一种载体治疗的动物相比,用反式互补载体治疗的动物有显著的生存获益。有趣的是,与单独用病毒反式互补系统治疗相比,给予GCV并没有进一步提高动物生存率,并且仅在反式互补载体治疗组中观察到长期生存。腹腔注射假野生型载体Ad.dl327会导致显著的肝毒性,而腹腔注射反式互补载体仅导致轻度肝脏异常。
使用E1和E4缺失的腺病毒载体组合的反式互补载体方法显示出与单价复制载体系统报道的类似抗肿瘤疗效,但通过要求细胞中同时存在两种载体以实现复制能力,可能通过降低有复制能力载体传播的风险而提供额外的安全性。